Autor: Wilson, Michael - Prolib Integro

Skocz do pozycji: 1.

Tytuł:: Annales Zoologici, vol. 55, no 3
Revision of the genus Semissus Melichar, 1906 (Hemiptera: Fulgoromorpha: Issidae)
Autorzy:: Gnezdilov, Vladimir Mihajlovič
Wilson, Michael R.
Współwytwórcy:: Polska Akademia Nauk. Muzeum i Instytut Zoologii
Fundacja "Natura optima dux"
Wydawca:: Fundacja Natura optima dux
Powiązania:: Annales Zoologici
Opis:: S. 421-428 : il. ; 27 cm
Bibliogr. s. 427-428
Nazwy taksonów w jęz. łac.
Taxa in Latin
Bibliogr. p. 427-428
P. 421-428 : ill. ; 27 cm
Dostawca treści:: RCIN - Repozytorium Cyfrowe Instytutów Naukowych

Książka

na półce

Skocz do pozycji: 2.

Autorzy:: Jang, Isabel
Agyemang, Charles A.
Carter, Rebekah E.
Sharp, Wilson
Sevigny, Sarah
Tou, Leila C.
Umair, Muhammad
Diaz, Michael J.
Opis:: Purpose: Coronaviruses (CoV) are single-stranded RNA viruses that transmit from animal species to humans, causing a threat to global health. We aim to summarize common imaging findings of 3 betacoronaviruses (b-CoVs) and the common clinical manifestation, to provide a better understanding of the courses of the disease. Material and methods: The Pubmed and Google Scholar databases were searched for the terms "SARS-CoV" OR "COVID-19" OR "MERS-CoV". Imaging-specific searches included keyword searches for "CT" AND "imaging". Clinical presentation-specific searches included keyword searches for "clinical" AND "manifestation" AND "cardiovascular" OR "neurology" OR "gastrointestinal" OR "hematology". In total, 77 articles were selected for discussion in the current literature review. Results: Human b-CoVs infection presented consistent indications of ground-glass opacities (GGO), consolidation, and interlobular septal thickening. Pleural effusion was also common in all 3 b-CoVs, but it was least present in SARS-CoV-2 infection. Bilateral lung involvement was common to both MERS-CoV and SARS-CoV-2 infection. Cardiovascular, neurological, haematological, and gastrointestinal were common clinical presentations found in patients infected with b-CoVs. Conclusions: The comparison of imaging findings can be applied in clinical practice to distinguish the 3 CoV through different imaging modalities. It is crucial to understand the possible imaging findings and clinical presentations to better understand the course of the disease as well as prepare for future variants.
Dostawca treści:: Repozytorium Uniwersytetu Jagiellońskiego

Artykuł

na półce

Skocz do pozycji: 3.

Tytuł:: Efficacy and Safety of Avatrombopag in Patients with Chronic Immune Thrombocytopenia : A Systematic Literature Review and Network Meta-Analysis
Autorzy:: Nazir, Jameel
Pustułka, Iwona
Tytuła, Anna
Vredenburg, Michael
Jurczak, Wojciech
Wilson, Koo
Mccrae, Keith R.
Smela, Beata
Wojciechowski, Piotr
Pochopien, Michał
Opis:: Introduction: A network meta-analysis (NMA) was performed to assess the efficacy and safety of avatrombopag, relative to eltrombopag, romiplostim, and fostamatinib, for patients with chronic immune thrombocytopenia (ITP) not responding adequately to corticosteroids. Methods: A systematic search of publication and clinical trial databases was conducted to identify relevant randomized controlled trials (RCTs) and observational studies. Data from eligible studies were extracted and analyzed in a Bayesian framework using relative effect sizes vs placebo. Outcomes included durable platelet response; need for rescue therapy; reduction in use of concomitant ITP medication; incidence of any or World Health Organization (WHO) grade 2–4 bleeding events, and any adverse events. Results were reported as odds ratios or incidence rate ratios (IRR) with 95% credible intervals (CrIs). Results: The NMA included seven phase 3 RCTs. Compared with placebo, avatrombopag was associated with statistically significant improvements in durable platelet response, reduction in use of concomitant ITP medication, and incidence of any bleeding events. Statistically significant differences vs placebo were also observed for durable platelet response and need for rescue therapy (eltrombopag, romiplostim, and fostamatinib); reduction in use of concomitant ITP medication (eltrombopag and romiplostim); incidence of any bleeding events (fostamatinib); and incidence of WHO grade 2–4 bleeding events (romiplostim and fostamatinib). No statistically significant differences were observed for any adverse events. Avatrombopag was associated with a statistically significant lower incidence of any bleeding events vs eltrombopag (IRR 0.38 [95% CrI 0.19, 0.75]) and romiplostim (IRR 0.38 [95% Crl 0.17, 0.86]); no other between-treatment differences were observed. Conclusion In this NMA, avatrombopag significantly increased the chance of achieving durable platelet response and reducing the use of concomitant ITP medication vs placebo, and significantly reduced the incidence of any bleeding events compared with placebo, eltrombopag, and romiplostim. The study aims to help guide clinicians managing patients with chronic ITP and insufficient response to previous treatment.
Dostawca treści:: Repozytorium Uniwersytetu Jagiellońskiego